Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
GENEVA, Switzerland, Aug. 05, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, today...
-
GENEVA, Switzerland, Aug. 04, 2021 (GLOBE NEWSWIRE) -- iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, today...
-
Project to investigate novel combination therapies in lymphoma with IOA-244IOA-244 Phase 1b clinical development in solid tumors initiated GENEVA, Switzerland, July 27, 2021 (GLOBE NEWSWIRE) --...
-
Safety, pharmacokinetic and pharmacodynamic readouts expected Q4 2021IOA-289 first ATX inhibitor to progress to clinic in oncology GENEVA, Switzerland, July 20, 2021 (GLOBE NEWSWIRE) -- iOnctura...